CVID Faculty & Research Interests
Research in my laboratory is focused on the functions of proteases, the powerful hydrolytic enzymes that regulate the activities of many cellular proteins in vascular biology, angiogenesis and cancer. Specifically, we aim to understand how membrane serine proteases and their inhibitors contribute to cell survival, differentiation and malignant transformation. This work will provide insight into basic mechanisms of cell behavior, and enable the development of new targets for therapeutic interventions.
Jonathan S. Bromberg, MD, PhD, a national leader in uncovering the secrets of the immune system in order to prevent rejection following organ transplants, has joined the University of Maryland School of Medicine as professor of surgery and microbiology and immunology. Dr. Bromberg is a kidney and pancreas transplant surgeon who will care for patients at the University of Maryland Medical Center. He will be the director of research in the Division of Transplantation and director of Strategic Services for Transplantation
Research in my laboratory is focused on understanding the mechanisms of action of anticancer agents, and is exploring the roles of receptor-stimulated reactive oxygen species in determining the fates of B-cells and lymphomas. Understanding this will help to design interventions to either protect helpful immune cells from unintended death (alleviating immunodeficiency), or to provoke carefully-controlled death of lymphomas.
My current research focuses on neuroimmune semaphorins 4A and 4D as immune checkpoints and critical regulators of chronic inflammation as observed in asthma or cancer. My group was first to report that these two Class IV semaphorin molecules play opposite roles in allergic asthma severity; Sema4A inhibited the disease whereas Sema4D potentiated its manifestation. We are in the process of developing Sema4A- and 4D-based immunotherapeutic strategies aimed at manipulation of their receptor-binding potentials. Another collaborative research project I am involved in Dr. Keegan’s laboratory examines the mechanisms of asthma exacerbation by respiratory syncytial virus with a focus on virus-activated long-lived M2-type macrophages.
Hematopoiesis is coordinated by key regulatory molecules that drive lineage-specific developmental programs. Current models depict lineage commitment as a process that involves cross-antagonism between blood cell programs, which promotes one lineage at the expense of the others. The long-term goal of my laboratory is to better define the molecular genetic strategies that regulate hematopoiesis. This goal is accomplished by studying how evolutionarily conserved factors regulate blood and heart cell development in the fruit fly, Drosophila melanogaster.
Research in my laboratory is focused on signaling by the cytokines IL-4 and IL-13. These cytokines regulate many functions including protection from apoptosis, regulation of allergy and asthma, and the control of myeloid development and function. This work will provide insight into better therapies for asthma, inflammation, and for certain cancers.
Dr. Kozar's research interests are in nutrition in the critically ill and endothelial dysfunction after hemorrhagic shock. She has published over 150 peer-reviewed articles and has been continuously funded by the NIH for almost 15 years. In addition to her role in the AAST, she serves as committee chair for the American College of Surgeons Verification Review Committee of the COT and the Women in Surgery Committee and is past President-elect of the Shock Society.
My Laboratory is focused on the structure and interactions of fibrin(ogen). Specifically, we aim to complete the high resolution structure of the fibrinogen molecule and establish molecular mechanisms of its interaction with Lipoprotein(a), endothelial cells and leukocytes. This work will provide insight into the role of fibrin(ogen) in such important physiological and pathological processes as inflammation, angiogenesis and atherogenesis.
I am interested in all aspects of vascular biology. Presently, my research focuses primarily on the formation of intimal hyperplasia. A normal blood vessel is a three-layer structure consisting of the intima, media, and adventitia. The intima is populated with endothelial cells. In the setting of trauma - including surgical bypass, angioplasty, or stenting - the normally quiescent, contractile medial smooth muscle cells dedifferentiate. These cells revert to a more primitive migratory, proliferative, and secretory phenotype. These cells migrate to the intima and cause the lesion observed in intimal hyperplasia. Intimal hyperplasia reduces vessel diameter and ultimately limits the patency of all cardiovascular reconstructions. We are presently focusing on methods of specifically inhibiting vascular smooth muscle cell migration and proliferation
Despite advances in open and endovascular surgery, a substantial number of patients suffer from limb loss or other vascular complications. This accentuates the need for improved understanding of the cellular and molecular basis of both beneficial and detrimental changes in blood vessels. My laboratory studies the regulation and role of matrix metalloproteinases in physiological and pathological responses to injury in the vasculature. We utilize clinically relevant models of vascular disease include resolution of deep venous thrombosis, collateral artery formation and limb ischemia. By adapting these models to the mouse, we have characterized a definitive role for individual proteases as well as transcription factors in these disease processes. We also utilize mouse models of clinically relevant conditions such as diabetes and hypercholesterolemia to determine how these common conditions affect these vascular processes. A newer area of investigation for our laboratory is how individual transcription factors alter vascular remodeling and how their activity can be modulated for potential therapeutic benefit.
Dr. Scalea is a multi-organ transplant surgeon and the director of pancreas and islet cell transplantation at the University of Maryland. At the University of Maryland, Dr. Scalea focuses on pancreas transplantation as well as autologous and allogeneic islet cell transplantation. He also works clinically on both the kidney and liver transplant teams. In addition to clinical work Dr. Scalea directs a translational immunology laboratory focused on novel methods for inducing transplantation tolerance. Dr. Scalea has published more than 40 peer reviewed publications in addition to multiple book chapters and published abstracts. Beyond basic science, Dr. Scalea has published on the topic of transplantation ethics in both the Atlantic and Readers' Digest.
Work in my laboratory focuses on inflammatory events that contribute to the progression of diseases such as atherosclerosis. Key modulators of these processes are low density lipoprotein (LDL) receptor family members. One member of this family, the LDL receptor-related protein (LRP) is a large cellular receptor that not only functions as an important cargo transporter, but also informs the cell of changes in its environment by mediating signaling responses. A goal of these studies is to understand the role of LRP and other LDL receptor family members in modulating cell signaling events and how this affects development of certain diseases, such as atherosclerosis and Alzheimers.
Dr. Ucizian's current research interest involves the study of aortic aneurysm and dissection in both animal and human studies. His team is studying the role of the endocytic receptor LRP1 in mediating the processes which lead to arterial wall degeneration and thus aneurysm and dissection formation.
Research in my laboratory is focused on the biology of a cytokine named TWEAK and its cell surface receptor named Fn14, with particular emphasis on the role of this ligand-receptor pair in cancer. We have found that TWEAK is expressed in tumors and that it can induce blood vessel formation (angiogenesis) in vivo, so one of our projects is focused on determining whether this cytokine could play a role in the process of tumor neovascularization, which is required for tumor growth and metastasis. Also, since our laboratory and others have reported that Fn14 is overexpressed in several tumor types and that Fn14 levels may influence tumor cell migration, a second project is focused on the role of Fn14 in cell invasion, an essential step in the metastatic cascade. Taken together, these studies will provide insight into whether TWEAK and/or Fn14 are potential molecular targets for cancer therapy.
I joined the Faculty at the University of Maryland Baltimore, School of Medicine, as a Research Associate in Dr. Medved’s laboratory in 2005. My current research focuses on the interactions of fibrin(ogen) with the VLDL receptor and VE-cadherin and their role in fibrin-dependent inflammation. In addition to its hemostatic function, fibrin(ogen), by interacting with different cell types through their various receptors and proteoglycans, also plays a prominent role in numerous (patho)physiological processes including inflammation. We have identified the VLDL receptor as a new receptor for fibrin and proposed a novel fibrin-VLDLR-dependent pathway of leukocyte transmigration which is a potential therapeutic target.
My laboratory has been investigating the molecular mechanism of tumor cell invasion by focusing on the regulation of actin polymerization, the driving force that facilitates the formation of membrane protrusions and the penetration of tumor cells into extracellular matrix. In particular, we have studied cortactin, a gene that plays a critical role in regulating the assembly of actin filaments at the foci of cellular protrusions. We showed that overexpression of cortactin, enhances metastasis and more recently that cortactin regulates cell motility and invasion by promoting membrane remodeling as well as intracellular trafficking of internalized receptors. This work has led us to investigate the mechanisms that regulate the function of cortactin by the oncogene Src and on a recently discovered cortactin binding protein called missing in metastasis (MIM). We aim to reveal the physiological and pathological role of MIM in cells and its role in tumor cell invasion.
Stem cells possess the ability to self-renew and to differentiate into multiple tissue types, and thus are ideal source of cells for tissue repair and regeneration. However, successful stem cell-based tissue regeneration depends on our ability to prepare a homogenous stem cell population and to overcome tissue rejection mediated by host immune cells. My research program comprises two separate projects: one is focused on the roles of mesenchymal stem cells in tissue repair/regeneration and the other is to study the roles of leukocytes in physiological processes such as innate and adaptive immune responses, and in development of such diseases as: atherosclerosis, myocardial infarction, stroke, and osteoporosis.